Akums Drugs and Pharmaceuticals Limited (IN:AKUMS)
:AKUMS
Want to see IN:AKUMS full AI Analyst Report?
Top Page
Akums Drugs and Pharmaceuticals Limited
(AKUMS)
Select Model
Select Model
Rating:73Outperform
Price Target:
₹660.00
▲(57.11% Upside)
Action:Upgraded
Date:06/11/26
The score is driven primarily by improved financial strength (especially reduced leverage and stronger recent cash generation) alongside a constructive technical uptrend. These positives are partially offset by a higher valuation (P/E ~35.5) and the risk signaled by FY26 margin compression and earnings/cash-flow volatility.
Positive Factors
Low leverage / strong balance sheet
The dramatic reduction in debt-to-equity to near-zero levels and a materially larger equity base provide durable financial flexibility. This lowers refinancing and covenant risk, supports capital spending or capacity additions, and strengthens resilience across industry cycles for multi-month planning horizons.
Negative Factors
Margin compression in FY26
A material fall in gross and net margins signals structural pressure from cost inflation, adverse product mix, or pricing constraints. If persistent, lower margins reduce free cash flow sustainability and the ability to fund expansion, making profitability more sensitive to volume cycles.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
The dramatic reduction in debt-to-equity to near-zero levels and a materially larger equity base provide durable financial flexibility. This lowers refinancing and covenant risk, supports capital spending or capacity additions, and strengthens resilience across industry cycles for multi-month planning horizons.
Read all positive factors
Akums Drugs and Pharmaceuticals Limited (AKUMS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹94.66B
Dividend YieldN/A
Average Volume (3M)11.50K
Price to Earnings (P/E)36.1
Beta (1Y)1.35
Revenue Growth5.85%
EPS Growth-25.45%
CountryIN
Employees7,536
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)12.42
Shares Outstanding157,393,980
10 Day Avg. Volume12,021
30 Day Avg. Volume11,497
Financial Highlights & Ratios
PEG Ratio-1.07
Price to Book (P/B)2.15
Price to Sales (P/S)1.64
P/FCF Ratio7.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)23.95
Revenue Forecast (FY)₹49.24B
Akums Drugs and Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Akums Drugs & Pharmaceuticals Ltd. is an Indian-based company, established in 2004 and headquartered in Delhi, that operates globally as a manufacturer and supplier of both finished pharmaceutical products and active pharmaceutical ingredients (AP...
How the Company Makes Money
AKUMS makes money mainly by providing contract manufacturing and related development services to pharmaceutical and healthcare companies that market products under their own brands. Its core revenue stream is manufacturing fees embedded in the sal...
Akums Drugs and Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
86
Very Positive
Cash Flow
72
Positive
| Breakdown | TTM | Mar 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.26B | 43.59B | 40.71B | 40.20B | 34.75B | 36.47B |
| Gross Profit | 7.62B | 9.37B | 16.05B | 14.37B | 11.67B | 12.69B |
| EBITDA | 2.39B | 6.31B | 5.29B | 1.31B | 3.09B | -821.80M |
| Net Income | 1.88B | 2.55B | 3.38B | -40.35M | 948.55M | -2.53B |
Balance Sheet | ||||||
| Total Assets | 51.59B | 54.47B | 41.13B | 35.16B | 32.67B | 30.69B |
| Cash, Cash Equivalents and Short-Term Investments | 16.78B | 17.10B | 5.82B | 2.88B | 1.50B | 1.03B |
| Total Debt | 902.87M | 1.57B | 882.12M | 5.65B | 6.19B | 3.95B |
| Total Liabilities | 19.91B | 21.16B | 10.50B | 27.96B | 25.43B | 24.44B |
| Stockholders Equity | 31.49B | 33.13B | 30.47B | 7.09B | 7.17B | 6.22B |
Cash Flow | ||||||
| Free Cash Flow | 13.13B | 9.80B | 1.93B | 1.87B | -1.52B | -2.26B |
| Operating Cash Flow | 15.47B | 12.11B | 4.65B | 4.98B | 1.77B | 318.54M |
| Investing Cash Flow | -12.71B | -9.69B | -5.48B | -3.30B | -3.05B | -2.35B |
| Financing Cash Flow | -5.29B | 430.11M | 727.88M | -1.08B | 1.25B | 2.36B |
Akums Drugs and Pharmaceuticals Limited Technical Analysis
Positive
420.10
Price Trends
540.57
Positive
503.64
Positive
476.21
Positive
Market Momentum
20.40
Negative
61.78
Neutral
66.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AKUMS, the sentiment is Positive. The current price of 420.1 is below the 20-day moving average (MA) of 555.00, below the 50-day MA of 540.57, and below the 200-day MA of 476.21, indicating a bullish trend. The MACD of 20.40 indicates Negative momentum. The RSI at 61.78 is Neutral, neither overbought nor oversold. The STOCH value of 66.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:AKUMS.
Akums Drugs and Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹94.66B | 36.08 | ― | ― | 5.85% | -25.45% | |
71 Outperform | ₹34.87B | 18.96 | ― | 0.96% | 9.30% | 14.06% | |
62 Neutral | ₹8.95B | 34.65 | ― | 1.96% | 8.23% | -33.30% | |
57 Neutral | ₹9.10B | 11.82 | ― | ― | 8.79% | 120.02% | |
56 Neutral | ₹3.70B | 32.96 | ― | ― | 3.26% | 167.18% | |
53 Neutral | ₹1.41B | 22.22 | ― | 1.62% | 2.83% | -26.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:AKUMS
Akums Drugs and Pharmaceuticals Limited
601.45
61.15
11.32%
IN:BAFNAPH
Bafna Pharmaceuticals Limited
156.50
81.50
108.67%
IN:BALPHARMA
Bal Pharma Limited
88.84
-8.23
-8.48%
IN:INDRAMEDCO
Indraprastha Medical Corporation Limited
380.35
-4.91
-1.27%
IN:KOPRAN
Kopran Limited
185.35
3.41
1.87%
IN:WANBURY
Wanbury Limited
260.45
-22.55
-7.97%
Akums Drugs and Pharmaceuticals Limited Corporate Events
ICRA Reaffirms Akums Ratings and Assigns Top Grade to New Commercial Paper
Apr 11, 2026
Akums Drugs and Pharmaceuticals Limited has had its long- and short-term working capital limits reaffirmed at [ICRA]AA (Stable) and [ICRA]A1+, while ICRA has also assigned an [ICRA]A1+ rating to the company’s proposed commercial paper progra...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.